ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $12.13M rose 42.9% year over year, ahead of the +26.0% change in trailing-twelve-month revenue. Sequentially, it rose 16.5% from the prior quarter. Over 3 fiscal years it compounded at +21.6% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $48.5M (+31.2%) for the fiscal year ending Dec 2026, a step up from the +17.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $12.13M+16.5% QoQ
- Last fiscal yearDec 2025
- $36.97M+17.8% YoY
- LTMMar 2026
- $40.61M+26.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +42.9% | +38.2% | -4.8 pp |
| 1 year | +17.8% | +31.2% | +13.4 pp |
| 3-year CAGR | +21.6% | +20.3% | -1.3 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 36.97M USD
- Year-over-year change
- +17.8%
- 4-year CAGR
- +22.7%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.97M | +17.8% |
| FY2024 | 2024-12-31 | 31.39M | +31.0% |
| FY2023 | 2023-12-31 | 23.96M | +16.6% |
| FY2022 | 2022-12-31 | 20.55M | +26.1% |
| FY2021 | 2021-12-31 | 16.3M | — |
Revenue vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +26.0% is the highest of 9, against a peer median of +3.6%.
- Over three fiscal years its annual growth of +21.6% compares with a peer median of +4.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | CA$937.39M CAD | +1.1% | +9.9% | |
| LTM Apr 2026 | $857.5M USD | +3.6% | -0.6% | |
| LTM Mar 2026 | $825.37M USD | +2.6% | +21.3% | |
| LTM Mar 2026 | $715.9M USD | +3.9% | +0.8% | |
| LTM Mar 2026 | $232.4M USD | +25.7% | -6.9% | |
| LTM Mar 2026 | $206.22M USD | +16.8% | +23.6% | |
| LTM Mar 2026 | $204.17M USD | +3.6% | +7.1% | |
| LTM Mar 2026 | $86.26M USD | -35.8% | -4.5% | |
| LTM Mar 2026 | $40.61M USD | +26.0% | +21.6% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding CLPT) | — | +3.6% | +4.0% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 16.3M | 20.55M | 23.96M | 31.39M | 36.97M |
| Cost of Revenue | 5.18M | 7.02M | 10.34M | 12.27M | 14.28M |
| Gross Profit | 11.12M | 13.53M | 13.61M | 19.12M | 22.69M |
| Gross Margin | 68.2% | 65.8% | 56.8% | 60.9% | 61.4% |
| Research & Development | 9.28M | 10.89M | 11.71M | 12.39M | 13.9M |
| Selling, General & Admin | 15.22M | 18.97M | 24.35M | 26.48M | 32.96M |
| Operating Expenses | 24.5M | 29.86M | 36.06M | 38.87M | 46.86M |
| Depreciation & Amortization | 692K | 777K | 1.46M | 1.9M | 2.24M |
| EBITDA | (12.75M) | (15.58M) | (20.63M) | (17.01M) | (20.86M) |
| EBITDA Margin | -78.2% | -75.8% | -86.1% | -54.2% | -56.4% |
| Operating Income | (13.37M) | (16.33M) | (22.45M) | (19.75M) | (24.16M) |
| Operating Margin | -82.1% | -79.5% | -93.7% | -62.9% | -65.4% |
| Interest Income | 0 | 0 | 386K | 872K | 1.21M |
| Interest Expense | 973K | 81K | 0 | 0 | 2.39M |
| Other Income / Expenses | (1.04M) | (103K) | 357K | 832K | (1.32M) |
| Income Before Tax | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.49M) |
| Pre-Tax Margin | -88.4% | -80.0% | -92.2% | -60.3% | -68.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 55K |
| Net Income | (14.41M) | (16.44M) | (22.09M) | (18.91M) | (25.54M) |
| Net Margin | -88.4% | -80.0% | -92.2% | -60.3% | -69.1% |
| EPS (Basic) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| EPS (Diluted) | (0.69) | (0.68) | (0.90) | (0.70) | (0.90) |
| Weighted Avg Shares | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
| Weighted Avg Shares (Diluted) | 20.73M | 24.18M | 24.61M | 27.03M | 28.32M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.